Latest News and Press Releases

Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline...

WARREN, N.J., May 12, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN). As the biopharma industry faces increasing competition from international markets...

kneat.com's Q1 shows continued strong growth and progress toward sustained profitability, ending the quarter with record revenue and a strong cash balance.

Transpire Bio has signed an agreement to expand the footprint of its R&D and Manufacturing capabilities in Pembroke Pines, Florida

Data published in Obesity journal show enhanced weight loss effect of NT-0796 when combined with semaglutide in preclinical obesity modelObese state completely reversed with 30% weight loss and...

Cohen Milstein Encourages Zenas BioPharma Investors Who Lost Money Following IPO Stock Collapse to Call Firm to Potentially Join or Lead Class Action.

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to...

Cohen Milstein Calls on Zenas BioPharma (ZBIO) Investors to Act Following Significant Post-IPO Losses

Zenas Biopharma Investors Urged to Contact Cohen Milstein After Post-IPO Losses

Investors who lost money on securities of Zenas BioPharma, Inc. (NASDAQ: ZBIO) encouraged to call Cohen Milstein.